company background image
MARI

Marinomed Biotech WBAG:MARI Stock Report

Last Price

€64.40

Market Cap

€97.0m

7D

-0.6%

1Y

-42.2%

Updated

13 Aug, 2022

Data

Company Financials +
MARI fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health1/6
Dividends0/6

MARI Stock Overview

Marinomed Biotech AG, a biopharmaceutical company, develops therapies for patients suffering from serious viral infectious diseases and autoreactive immune disorders in Austria, other European countries, and internationally.

Marinomed Biotech Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Marinomed Biotech
Historical stock prices
Current Share Price€64.40
52 Week High€119.50
52 Week Low€58.60
Beta0.091
1 Month Change0.94%
3 Month Change-6.67%
1 Year Change-42.24%
3 Year Change-34.95%
5 Year Changen/a
Change since IPO-15.26%

Recent News & Updates

Shareholder Returns

MARIAT PharmaceuticalsAT Market
7D-0.6%-2.3%1.6%
1Y-42.2%-1.3%-6.7%

Return vs Industry: MARI underperformed the Austrian Pharmaceuticals industry which returned -1.3% over the past year.

Return vs Market: MARI underperformed the Austrian Market which returned -6.7% over the past year.

Price Volatility

Is MARI's price volatile compared to industry and market?
MARI volatility
MARI Average Weekly Movement5.1%
Pharmaceuticals Industry Average Movement5.8%
Market Average Movement4.9%
10% most volatile stocks in AT Market7.2%
10% least volatile stocks in AT Market2.8%

Stable Share Price: MARI is not significantly more volatile than the rest of Austrian stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: MARI's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200642Andreas Grassauerhttps://www.marinomed.com

Marinomed Biotech AG, a biopharmaceutical company, develops therapies for patients suffering from serious viral infectious diseases and autoreactive immune disorders in Austria, other European countries, and internationally. It operates through two segments, Carragelose and Marinosolv. The company develops Marinosolv, a technology platform that increases the bioavailability of hardly soluble compounds for the treatment of sensitive tissues, such as eyes and nose; and.

Marinomed Biotech Fundamentals Summary

How do Marinomed Biotech's earnings and revenue compare to its market cap?
MARI fundamental statistics
Market Cap€97.00m
Earnings (TTM)-€5.63m
Revenue (TTM)€11.82m

8.2x

P/S Ratio

-17.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MARI income statement (TTM)
Revenue€11.82m
Cost of Revenue€9.77m
Gross Profit€2.05m
Other Expenses€7.68m
Earnings-€5.63m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Aug 25, 2022

Earnings per share (EPS)-3.74
Gross Margin17.32%
Net Profit Margin-47.65%
Debt/Equity Ratio-3,684.5%

How did MARI perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is MARI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MARI?

Other financial metrics that can be useful for relative valuation.

MARI key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue9.1x
Enterprise Value/EBITDA-24.2x
PEG Ration/a

Price to Sales Ratio vs Peers

How does MARI's PS Ratio compare to its peers?

MARI PS Ratio vs Peers
The above table shows the PS ratio for MARI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average2.7x
530199 Themis Medicare
2xn/a₹7.4b
506879 Gujarat Themis Biosyn
5.7xn/a₹7.3b
STHZ StateHouse Holdings
1.5x58.4%CA$126.2m
APPH Apontis Pharma
1.8x16.4%€92.7m
MARI Marinomed Biotech
8.2x24.9%€97.0m

Price-To-Sales vs Peers: MARI is expensive based on its Price-To-Sales Ratio (8.2x) compared to the peer average (2.7x).


Price to Earnings Ratio vs Industry

How does MARI's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

Price-To-Sales vs Industry: MARI is expensive based on its Price-To-Sales Ratio (8.2x) compared to the European Pharmaceuticals industry average (4.1x)


Price to Sales Ratio vs Fair Ratio

What is MARI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MARI PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio8.2x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate MARI's Price-To-Sales Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of MARI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: MARI (€64.4) is trading below our estimate of fair value (€260.84)

Significantly Below Fair Value: MARI is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Marinomed Biotech forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


8.2%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MARI is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MARI is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MARI is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MARI's revenue (24.9% per year) is forecast to grow faster than the Austrian market (-1.1% per year).

High Growth Revenue: MARI's revenue (24.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if MARI's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Marinomed Biotech performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


8.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: MARI is currently unprofitable.

Growing Profit Margin: MARI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MARI is unprofitable, but has reduced losses over the past 5 years at a rate of 8.5% per year.

Accelerating Growth: Unable to compare MARI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MARI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (18.2%).


Return on Equity

High ROE: MARI's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Discover strong past performing companies

Financial Health

How is Marinomed Biotech's financial position?

Financial Health Score

1/6

Financial Health Score 1/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: MARI has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: MARI has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: MARI has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: MARI's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MARI has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if MARI has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies

Dividend

What is Marinomed Biotech current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate MARI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MARI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MARI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MARI's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MARI has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

4.0yrs

Average management tenure


CEO

Andreas Grassauer (53 yo)

16.58yrs

Tenure

€324,000

Compensation

Mr. Andreas Grassauer, PhD, is a Co-Founder of Marinomed Biotechnology GmbH in 2006 and serves as its Chairman of Management Board and has been Chief Executive Officer since 2006. Mr. Grassauer has co-foun...


CEO Compensation Analysis

Compensation vs Market: Insufficient data to establish whether Andreas's total compensation is reasonable compared to companies of similar size in the Austrian market.

Compensation vs Earnings: Andreas's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: MARI's management team is considered experienced (4 years average tenure).


Board Members

Experienced Board: MARI's board of directors are considered experienced (4.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2%.


Top Shareholders

Company Information

Marinomed Biotech AG's employee growth, exchange listings and data sources


Key Information

  • Name: Marinomed Biotech AG
  • Ticker: MARI
  • Exchange: WBAG
  • Founded: 2006
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: €96.997m
  • Shares outstanding: 1.51m
  • Website: https://www.marinomed.com

Number of Employees


Location

  • Marinomed Biotech AG
  • Hovengasse 25
  • Korneuburg
  • Lower Austria
  • 2100
  • Austria

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/13 00:00
End of Day Share Price2022/08/12 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.